The ASCO Foundation works with ASCO to raise and distribute funds for programs that improve cancer care and help to create the environment for prevention and cure. Since its inception, the ASCO Foundation Grants Program has awarded some $40 million to young and mid-career physicians working on cutting-edge projects.
“This is an exciting time in the field of clinical oncology as cancer research and treatments continue to progress, and we are helping to improve the lives of those living with cancer,” said Dr. Bailes, a member of OT's Editorial Board. “Working with the ASCO Foundation's remarkable staff and board of directors is a wonderful opportunity, and I look forward to supporting continued advancement in the field of oncology in my new role as chair.”
Daniel F. Hayes, MD, Professor of Internal Medicine and Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center, is the first recipient of the Gianni Bonadonna Breast Cancer award, given by the American Society of Clinical Oncology and the ASCO Foundation and supported by a grant from GlaxoSmithKline Oncology.
The award and fellowship includes a $10,000 cash prize, given to an active clinical or translational researcher with a distinguished record of accomplishments in the breast cancer field. The award was given at ASCO's first Breast Cancer Symposium, held last month in San Francisco.
During the past two decades, Dr. Hayes has helped bridge the gap between laboratory and clinical research, becoming an internationally recognized leader in the use of the CA15-3 blood test and other tumor markers, such as HER-2. More recently, he and his colleagues have reported groundbreaking results in two areas of research: circulating tumor cells in metastatic breast cancer and the pharmacogenomics of tamoxifen.
He is widely considered to be an expert in the field of clinical breast cancer research, especially in regard to new hormonal and chemotherapeutic treatments, and, in particular, development, evaluation, and clinical use of tumor markers. He was a charter member of ASCO's Tumor Marker Guideline Expert Panel, which he has co-chaired for the past three years.
“I am honored to be the first recipient of the Gianni Bonadonna Breast Cancer Award,” Dr. Hayes said. “Few researchers have had the impact on cancer advancements that Dr. Bonadonna has, and I accept this award with the full intent of honoring his legacy and life's work with continued efforts to improve the care and treatment of patients.”
Dr. Bonadonna, of the Instituto Nazionale Tumori in Milan, conducted the pivotal cyclophosphamide, methotrexate, and fluorouracil (CMF) trial that ushered in the widespread acceptance of adjuvant chemotherapy as part of the curative treatment of breast cancer, a finding that changed the course of how breast cancer is treated. He also designed and conducted the first clinical trials exploring the use of doxorubicin and developed the doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) protocol, which remains the gold standard for treating Hodgkin's disease.
Samuel Waxman, MD, Founder and Scientific Director of the Samuel Waxman Cancer Research Foundation, has been named Distinguished Service Professor by Mount Sinai School of Medicine. Dr. Waxman, who is a Professor of Medicine at the school, was honored at the institution's 22nd Annual Convocation Ceremony September 18.
Michael A. Caligiuri, MD, Director of Ohio State University Comprehensive Cancer Center, has been elected to a two-year term as Vice-President and President-elect of the Association of American Cancer Institutes. He will succeed Edward J. Benz, Jr, MD, of Dana-Farber Cancer Institute and will begin serving an additional two-year term as President of the AACI in October 2009.
The AACI also elected the following members to serve three-year terms on the Board of Directors beginning this month: Timothy J. Eberlein, MD, Director of the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University Medical Center; Craig B. Thompson, MD, Director of the Abramson Cancer Center of the University of Pennsylvania and Associate Vice-President for Cancer Services for the University of Pennsylvania Health System; Donald L. Trump, MD, President and CEO of Roswell Park Cancer Institute; and Cheryl L. Willman, MD, Director and CEO of the University of New Mexico Cancer Center.
Thomas V. O'Halloran, PhD, has been named Associate Director for Basic Sciences at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Dr. O'Halloran is currently Director of the Chemistry of Life Processes Institute and the Charles E. and Emma H. Morrison Professor in the Department of Chemistry and the Department of Biochemistry, Molecular Biology, and Cell Biology. He succeeds Teresa K. Woodruff, PhD, who is stepping down to focus on her positions as Executive Director of the Institute for Women's Health Research and Chief of the Division of Fertility Preservation.
Sai Yendamuri, MD, has been appointed staff physician in the Thoracic Division of the Department of Surgery at Roswell Park Cancer Institute, after completing his residency in cardiothoracic surgery at the University of Texas M. D. Anderson Cancer Center.
Candace S. Johnson, PhD, has been appointed Chair of the Department of Pharmacology and Therapeutics at Roswell Park Cancer Institute. Dr. Johnson has been a senior faculty member and Senior Vice-President of Translational Research since 2002. She was endowed as the Robert, Lew and Ann Wallace Chair in Translational Research in 2005.
Richard L. Crownover, MD, PhD, has been appointed Associate Professor in Radiation Oncology at the Cancer Therapy & Research Center and the University of Texas Health Science Center at San Antonio and has opened his own practice there. He was previously Director of the Regional Cancer Center for the Reading (PA) Hospital and Medical Center.
Beth Y. Karlan, MD, Director of Cedars-Sinai Women's Cancer Research Institute in Los Angeles, has been named Editor-in-Chief of Gynecologic Oncology, the medical journal of the Society of Gynecologic Oncologists. She succeeds David M. Gerhenson, MD, who has led the journal for 17 years, and will begin her editorship January 1, 2008.
To Reach Oncology Times
© 2007 Lippincott Williams & Wilkins, Inc.
- ▪ For Editorial, Permissions, or Publishing Matters:
- Oncology Times, 333 Seventh Ave., 19th Floor, New York, NY 10001 646-674-6544, fax 646-674-6500; e-mail: firstname.lastname@example.org
- ▪ For Circulation Matters:
- To cancel a subscription, change your address or for other subscription services, please call: 800-430-5450, fax: 800-383-1781, send an e-mail to: email@example.com or send a written request to: Oncology Times, 2340 River Rd., Ste 408, Des Plaines, IL 60019-9883.
- ▪ For Classified Advertising:
- Melissa Moody, LWW; 351 West Camden, Baltimore, MD 21201 800-269-4339, fax 410-528-4452 e-mail: Melissa.Moody@wolterskluwer.com
- ▪ For Information about Reprints:
- Pharmaceutical Media Inc
- 30 East 33rd St
- New York, NY 10016
More on ONCOLOGY-TIMES.com...